Level of High-Sensitive Cardiac Troponin I and Value for Predicting Clinical Outcomes in Supraventricular Tachycardia Patients
Article Sidebar
Main Article Content
Abstract
Background: Supraventricular Tachycardia (SVT) can cause High Sensitive Cardiac Troponin I (hs-cTnI ) elevate even absent of myocardial infarction. However, information aboutassociation between cardiovascular illness and level of hs-cTnI in SVT patient were limited.
Objective: This study aims to determine correlation between hs-cTnI level and cardiovascular outcomein SVT patient.
Methods: This single-center retrospective descriptive study was conducted in Surin hospital, Surin province, Thailand. Data between January 1st 2017 to April 30th 2021 were selected by using ICD10 I47.1 as principle diagnosis. Inclusion criteria were age between 15-90 year-old patients and at least one test of hs-cTnI was present. Cardiovascular illness was collected from latest available medical records.
Results: Total 618 patients were diagnosed SVT and 261 patients were met inclusion criteria.One-hundred and forty nine (69.0%) had positive hs-cTnI (normal range were less than 19.8 ng/L in male and 11.6 ng/L in female). The median of hs-cTnI was 19.7 ng/L (range 0.0-2776.9 ng/L). There was no association between gender, age, hemoglobin level, estimated Glomerular Filtration Rate ; eGFR), methods of SVT treatment, duration from onset of SVT, cardiomegaly by chest X-ray, pre-existing hypertension, diabetes mellitus, valvular heart disease, previous myocardial infarction, initial blood pressure less than 90/60 or more than 180/120 mmHg and level of hs-cTnI (p=.96). Every patients can be discharged from hospital without any death. Mean follow-up time was 20.0 ± 14.2 months. Sixty-four (28.6%)patients develop new cardiovascular disease, mainly was recurrent SVT (81.3%).There was no any correlation between hs-cTnI level and new-cardiovascular disease (p=.58)
Conclusion: There was no correlation between hs-cTnI level and new cardiovascular event in SVT patients within 20 weeks follow up.
Keywords: Supraventricular Tachycardia, High Sensitive Cardiac Troponin I
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Vasile VC, Jaffe AS. High-Sensitivity Cardiac Troponin for the Diagnosis of Patients with Acute Coronary Syndromes. Curr Cardiol Rep 2017;19(10):92. doi: 10.1007/s11886-017-0904-4
Giannitsis E, Katus HA. Cardiac troponin level elevations not related to acute coronary syndromes. Nat Rev Cardiol 2013;10(11):623-34. doi: 10.1038/nrcardio.2013.129
Sayadnik M, Shafiee A, Jenab Y, Jalali A, Sadeghian S. Predictors of High-Sensitivity Cardiac Troponin T Elevation in Patients with Acute Paroxysmal Supraventricular Tachycardia and Ischemic Heart Disease. Tex Heart Inst J 2017;44(5):306-11. doi: 10.14503/THIJ-15-5338
Patane S, Marte F, Di Bella G. Abnormal troponin I levels after supraventricular tachycardia. Int J Cardiol 2009;132(2):e57-9. doi: 10.1016/j.ijcard.2007.07.120
Zellweger MJ, Schaer BA, Cron TA, Pfisterer ME, Osswald S. Elevated troponin levels in absence of coronary artery disease after supraventricular tachycardia. Swiss Med Wkly 2003;133(31-32):439-41.
Carlberg DJ, Tsuchitani S, Barlotta KS, Brady WJ. Serum troponin testing in patients with paroxysmal supraventricular tachycardia: outcome after ED care. Am J Emerg Med. 2011;29(5):545-8. doi: 10.1016/j.ajem.2010.01.041
Wood K. Mechanisms and clinical manifestations of supraventricular tachycardias. Prog Cardiovasc Nurs. 1995;10(2):3-14.
Ghersin I, Zahran M, Azzam ZS, Suleiman M, Bahouth F. Prognostic value of cardiac troponin levels in patients presenting with supraventricular tachycardias. J Electrocardiol. 2020;62:200-3. doi: 10.1016/j.jelectrocard.2020.09.001
Gore MO, Seliger SL, Defilippi CR, Nambi V, Christenson RH, Hashim IA, et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol 2014;63(14):1441-8. doi: 10.1016/j.jacc.2013.12.032
Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367. doi: 10.1093/eurheartj/ehaa575.
Yan I, Borschel CS, Neumann JT, Sprunker NA, Makarova N, Kontto J, et al. High-Sensitivity Cardiac Troponin I Levels and Prediction of Heart Failure: Results From the Biomar CaRE Consortium. JACC Heart Fail. 2020;8(5):401-11. doi: 10.1016/j.jchf.2019.12.008.
